S A Eccles
Overview
Explore the profile of S A Eccles including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
1774
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Eccles S
J Mammary Gland Biol Neoplasia
. 2002 May;
6(4):393-406.
PMID: 12013529
Gene amplification and/or overexpression of the c-erbB-2/HER2/neu tyrosine kinase are linked with poor prognosis in breast cancer. This is manifest in shorter disease-free intervals, increased risk of metastasis, and resistance...
12.
O-Charoenrat P, Rhys-Evans P, Archer D, Eccles S
Oral Oncol
. 2002 Jan;
38(1):73-80.
PMID: 11755824
We studied the profile of four c-erbB receptors in head and neck squamous cell carcinomas (HNSCC) and to determine whether their expression was associated with clinicopathological features and key molecules...
13.
George M, Padhani A, Brown G, Tait D, Eccles S, Swift R
Br J Surg
. 2001 Dec;
88(12):1628-36.
PMID: 11736977
Background: Tumour neoangiogenesis can be assessed non-invasively by measuring angiogenic cytokine concentrations in peripheral circulation and by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). The aim of this study was to...
14.
George M, Tutton M, Janssen F, Arnaout A, Abulafi A, Eccles S, et al.
Neoplasia
. 2001 Nov;
3(5):420-7.
PMID: 11687953
We aimed to assess the relationship of the angiogenic cytokines VEGF-A, VEGF-C, and VEGF-D and their receptors VEGFR-2 and VEGFR-3 in the adenoma-carcinoma sequence and in metastatic spread of colorectal...
15.
O-Charoenrat P, Rhys-Evans P, Eccles S
Cancer
. 2001 Aug;
92(3):556-68.
PMID: 11505400
Background: The expression of vascular endothelial growth factor (VEGF)-A isoforms (121, 165, 189, 206), VEGF-B, VEGF-C and VEGF-D in both experimental and clinical models of head and neck squamous cell...
16.
O-Charoenrat P, Rhys-Evans P, Eccles S
Arch Otolaryngol Head Neck Surg
. 2001 Aug;
127(7):813-20.
PMID: 11448356
Background: Matrix metalloproteinases (MMPs) have been implicated in the invasion and metastasis of head and neck squamous cell carcinoma (HNSCC). However, a detailed analysis of MMPs and tissue inhibitors of...
17.
Eccles S
Breast Cancer Res
. 2001 Mar;
3(2):86-90.
PMID: 11250751
The first monoclonal antibodies (mAbs) approved for cancer therapy are now in Phase II and III trials, but the critical mechanism(s) determining efficacy and response in patients are still largely...
18.
O-Charoenrat P, Rhys-Evans P, Modjtahedi H, Eccles S
Clin Exp Metastasis
. 2001 Mar;
18(2):155-61.
PMID: 11235991
Aberrant expression of tyrosine kinases such as c-erbB and EGFR contributes to the progression of head and neck squamous cell carcinomas (HNSCCs). One mechanism may be potentiation of angiogenesis, since...
19.
20.
George M, Eccles S, Tutton M, Abulafi A, Swift R
Clin Cancer Res
. 2000 Aug;
6(8):3147-52.
PMID: 10955796
Most studies measuring circulating vascular endothelial growth factor (VEGF) have sampled serum rather than plasma. There has been much debate whether the collection of sera (which causes the activation of...